middle.news
Recce Pharmaceuticals Advances Phase 3 Trial and Secures A$6.75m R&D Rebate
5:55pm on Sunday 1st of June, 2025 AEST
•
Pharmaceuticals
Read Story
Recce Pharmaceuticals Advances Phase 3 Trial and Secures A$6.75m R&D Rebate
5:55pm on Sunday 1st of June, 2025 AEST
Key Points
Regulatory and ethics approvals obtained for Phase 3 trial of RECCE® 327 in Indonesia
Patient dosing completed for Phase II ABSSSI clinical trial with data expected Q1 2025
Received A$6.75 million Australian R&D tax incentive rebate
Australian patent granted for RECCE® anti-infectives, securing IP protection through 2037
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RECCE PHARMACEUTICALS (ASX:RCE)
OPEN ARTICLE